Founded in 1999 in Copenhagen, Genmab A/S has risen to become a global leader in the field of biotechnology, particularly in the development of antibody-based cancer therapies. As one of the most prominent biotech firms in Denmark and indeed across Europe, Genmab embodies the fusion of cutting-edge scientific innovation and commercially viable pharmaceutical development. The company is headquartered in Denmark but operates international offices and research facilities in the Netherlands, the United States, and Japan.
Genmab’s impact extends far beyond national borders. The company is publicly traded on Nasdaq Copenhagen under the ticker “GMAB” and boasts a market capitalization of over DKK 200 billion (around USD $30 billion) as of 2024. With a workforce exceeding 2,000 employees across continents, Genmab is not merely a symbol of Denmark’s scientific innovation. It’s a major player in the global pharmaceutical and life sciences arena.
Here are the key points on Genmab A/S:
- Genmab A/S: A Danish Biotechnology Powerhouse: Founded in 1999 in Copenhagen, Genmab has grown into a global leader in antibody-based cancer therapies. This is with international offices and a revenue of over USD $2.6 billion in 2023.
- Genmab’s Role in Denmark’s Biotech Sector: Part of Medicon Valley, Genmab boosts Denmark’s reputation in biotech innovation. They focus on oncology and fostering domestic growth through proprietary platforms and strategic partnerships.
- Pioneering Cancer Treatments with Blockbusters: Genmab is known for its successful therapies like Daratumumab (Darzalex®), generating over USD $8 billion annually, and Tivdak®, a breakthrough in cervical cancer treatment.
- Proprietary Technologies Driving Innovation: Genmab’s DuoBody®, HexaBody®, and HexElect® platforms enable the development of next-generation antibody therapeutics with enhanced targeting and immune activation.
Genmab A/S: Positioning Denmark as a Biotech Innovator
Alongside other notable Danish firms such as Novo Nordisk and Lundbeck, Genmab helps constitute what’s often referred to as the country’s “Medicon Valley.” Medicon Valley is one of Europe’s strongest life sciences clusters. However, while Novo Nordisk focuses on diabetes and rare diseases, Genmab plays a crucial role in shaping the future of oncology.
What makes Genmab particularly important to Denmark is its unique role in sparking domestic pharmaceutical innovation. Unlike many biotech firms that focus purely on research and then license out their technologies, Genmab follows a more integrated model. It combines proprietorship of novel platforms with strategic partnerships. Hence, allowing for both value creation in Denmark and sustainable long-term growth overseas. In 2023 alone, Genmab reported net revenues exceeding DKK 18 billion (USD $2.6 billion).
Pioneering Cancer Treatments
Genmab is best known for its suite of revolutionary monoclonal antibody treatments. Perhaps the most well-known product associated with Genmab is Daratumumab. This medication, designed for the treatment of multiple myeloma—a cancer of the plasma cells—has become a groundbreaking therapy. It is used globally in patients with relapsed and refractory forms of the disease. As of 2023, Darzalex generated annual sales of over USD $8 billion worldwide.
Another therapeutic breakthrough attributed to Genmab is Tisotumab vedotin, a first-in-class antibody-drug conjugate (ADC). It is marketed under the name Tivdak in collaboration with Seagen (now part of Pfizer). Also, it is approved in the United States for patients with recurrent or metastatic cervical cancer.
A Model of Danish Innovation with Global Reach
Genmab represents a model of how a Danish company can succeed globally while retaining its scientific and corporate foundations in Denmark. Its success has inspired countless startups in Denmark’s bio and medtech sectors. Consequently, acting as an anchor institution for talent and investment. Furthermore, the company contributes significantly to Denmark’s economy.
In global terms, Genmab stands among a small elite of biotech companies that deliver clinical promise and commercial viability through a platform-based approach. Its diverse pipeline targets a range of cancers from hematological malignancies to solid tumors. This is with multiple early-stage and mid-stage candidates in clinical trials. Genmab’s proprietary technology platforms—such as the DuoBody® and HexaBody® platforms—set it apart from industry peers by enabling the creation of next-generation antibody therapeutics that outperform traditional monoclonal antibodies.
Genmab A/S Offers a Future Centered on Sustainable Innovation
Sustainability and long-term vision are core to Genmab’s operational philosophy. The company has laid out ambitious plans for its pipeline expansion. Therefore, aiming to have five products on the market and diagnostics for at least two types of cancer developed by 2030. It continues to invest heavily in research and development. Hence, allocating nearly 40% of its total revenue toward R&D activities annually. This commitment not only places Genmab at the forefront of biotech innovation. It also ensures that scientific breakthroughs translate into real-world therapies, improving patient outcomes globally.
Products and Services of Genmab A/S
Innovative Antibody Therapeutics at the Core
At the heart of Genmab A/S’s success lies its robust portfolio of therapeutic antibodies. They are designed to harness and enhance the body’s immune system in the fight against cancer. Genmab specializes in both standalone monoclonal antibodies and next-generation antibody platforms. And these form the backbone of its product lineup and research activities.
Genmab’s products are used globally in treating various types of cancers, many of which previously had limited or no effective therapies. The company follows a dual commercial strategy—developing some drugs independently. This is while partnering with multinational pharmaceutical firms such as Johnson & Johnson, Pfizer, and AbbVie for co-development and commercialization of others.
Blockbuster: Daratumumab (Darzalex®)
The most commercially successful product associated with Genmab is Daratumumab, marketed under the brand name Darzalex®. This is a first-in-class, human CD38-directed monoclonal antibody discovered by Genmab. And it was later licensed to Janssen Biotech (a Johnson & Johnson subsidiary). Approved initially by the U.S. FDA in 2015 for multiple myeloma, Darzalex has since been approved in over 100 countries. And it is available in multiple formulations, including intravenous and subcutaneous delivery.
Darzalex works by targeting the CD38 protein, a surface marker that is highly expressed on multiple myeloma cells. By binding to this protein, it triggers the immune system to destroy cancerous cells. Its subcutaneous formulation, Darzalex Faspro®, offers patients a quicker and more convenient alternative to intravenous infusions. Thereby, reducing administration time from hours to just a few minutes.
From a revenue standpoint, the success of Darzalex is striking. In 2023, global sales of Darzalex surpassed USD $8 billion. Subsequently, making it one of the top-selling oncology therapies in the world and one of the most valuable drugs to emerge from a Danish biotech pipeline.
Tivdak® – A Milestone in Women’s Cancer Treatment
Another flagship product in Genmab’s commercial portfolio is Tisotumab vedotin, marketed as Tivdak®. This antibody-drug conjugate (ADC) represents a significant breakthrough in the treatment of recurrent or metastatic cervical cancer, especially for patients who have relapsed after chemotherapy.
Developed in collaboration with Seagen (a company now under Pfizer), Tivdak™ combines Genmab’s expertise in antibody engineering with the cytotoxic potential of targeted chemotherapy. It uses a tissue-factor targeting antibody linked to a microtubule-inhibiting agent, allowing it to selectively deliver the payload to cancer cells and spare healthy tissue.
Approved by the FDA in 2021 under an accelerated approval pathway, Tivdak is currently undergoing further clinical trials to validate its efficacy across broader patient populations. The therapeutic’s arrival represented a turning point for cervical cancer patients, many of whom previously lacked effective second-line treatment options.
Proprietary Technologies: DuoBody®, HexaBody®, HexElect® and Beyond
One of Genmab’s most distinguishing features is its robust suite of proprietary antibody technology platforms, which are the engines behind current and future product developments. These platforms empower Genmab and its partners to engineer the next generation of antibody-based therapies with improved targeting, reduced side effects, and superior immune-activating properties.
- DuoBody® Platform: This technology allows the creation of bispecific antibodies—molecules capable of binding to two different antigens simultaneously. Bispecific antibodies can bring immune cells directly into contact with cancer cells, which enhances the immune response and effectiveness of therapy. Several drugs in Genmab’s pipeline are based on this platform, including Epcoritamab.
- HexaBody® Platform: A transformative technology that improves the natural ability of antibodies to surround and kill cancer cells by enhancing their interaction with immune effectors. HexaBody-modified antibodies can form strong hexameric structures, leading to more powerful activation of immune system pathways such as the complement cascade.
- HexElect® Platform: Designed to add a further level of specificity, HexElect enables antibody therapies to be active only when they bind to two different targets simultaneously. This provides highly targeted immune activation and reduces potential off-target toxicity, addressing one of the major challenges in oncology treatments.
Pipeline of Tomorrow’s Therapies
Genmab’s research pipeline includes a broad spectrum of therapeutic candidates, many of which are in mid-to-late stage clinical trials. These include:
- Epcoritamab (DuoBody®-CD3xCD20): A subcutaneous bispecific antibody developed with AbbVie for the treatment of diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies. Epcoritamab has shown promising results in clinical trials and received regulatory approvals in both the US and Europe.
- GEN1046 and GEN1042: These investigational bispecific antibodies target PD-L1 and 4-1BB or CD40, aiming to enhance antitumor immune responses. They are currently in clinical development for multiple solid tumors, including lung and colorectal cancer.
- GEN3014 (HexaBody-CD38): A next-generation CD38 antibody currently in development for multiple myeloma. It is designed to be more potent than Daratumumab by using Genmab’s HexaBody technology.
The current pipeline includes more than 20 investigational products at various stages of development, demonstrating Genmab’s strong foothold in immuno-oncology and its commitment to pushing the envelope far beyond conventional therapies.
Contractual Partnerships and Licensing
Genmab also generates significant revenue through licensing its proprietary technologies and co-developing products with major pharmaceutical companies. Its collaborations with firms like Johnson & Johnson, AbbVie, Seagen, BioNTech, and others span several years and product types, with some agreements including milestone payments, royalties on sales, and shared commercial responsibilities.
These partnerships are not just financially strategic; they also enable Genmab to scale its innovations globally, benefiting from the commercial prowess and regulatory infrastructure of its partners.
Supporting Infrastructure and Services
In addition to product development, Genmab offers extensive capabilities in cutting-edge preclinical and clinical research. With dedicated R&D centers in Copenhagen, Utrecht, Princeton (New Jersey), and Tokyo, the company maintains world-class facilities focused on antibody discovery, translational medicine, and bioinformatics. Genmab also invests heavily in biomarker development and personalized medicine, supporting the emergence of data-driven immunotherapies.
While Genmab does not currently offer medical services or diagnostics directly to patients, its contributions to the broader ecosystem of cancer care—particularly in the areas of immunology and precision medicine—are invaluable. Through academic partnerships, sponsored clinical studies, and publication of research, Genmab plays a vital role in the scientific and medical advancement of cancer therapeutics.
Conclusion: Genmab A/S
Genmab A/S stands as one of Denmark’s most remarkable success stories in the biotechnology sector. From its inception in Copenhagen in 1999 to its current status as a multibillion-dollar enterprise with a global footprint, Genmab has demonstrated the powerful synergy between scientific innovation, strategic collaboration, and business excellence. The company’s pioneering antibody-based therapies—particularly Daratumumab and Tivdak—have addressed critical unmet needs in oncology and saved or extended the lives of thousands of patients around the world.
Genmab’s true strength lies in its continued investment in next-generation antibody technologies, such as DuoBody®, HexaBody®, and HexElect®, which support an expanding pipeline of future potential blockbuster drugs. As a leading innovator and partner to global pharmaceutical leaders, Genmab not only contributes significantly to patient care but also places Denmark firmly on the global map as a hub of biomedical innovation.
Frequently Asked Questions about Genmab A/S
1. What does Genmab A/S do?
Genmab A/S is a biotechnology company that specializes in the research, development, and commercialization of antibody-based therapies, primarily for the treatment of cancer. Also, it develops innovative monoclonal antibodies and antibody-drug conjugates using proprietary platforms.
2. Who are Genmab’s main partners?
Genmab A/S collaborates with several major pharmaceutical companies including Johnson & Johnson (Janssen), AbbVie, Pfizer (after acquisition of Seagen), and BioNTech. These partnerships often involve joint development and commercialization of therapies.
3. What are the DuoBody® and HexaBody® platforms?
DuoBody® is Genmab’s technology for making bispecific antibodies that can target two antigens at once. Therefore, improving therapeutic effectiveness. HexaBody® is a platform that enhances the immune system’s ability to eliminate cancer cells through improved antibody functionality.
4. How big is Genmab A/S in terms of market value?
As of 2024, Genmab A/S has a market capitalization exceeding DKK 200 billion (approximately USD $30 billion). Thus, making it one of the largest publicly traded biotechnology firms in Europe.
5. Is Genmab A/S a profitable company?
Yes. Genmab A/S has achieved commercial success (primarily through royalty-generating products like Darzalex). And it continues to grow its revenue base while maintaining a strong focus on research and development.
6. What makes Genmab A/S important for Denmark?
Genmab A/S showcases Denmark’s leadership in life sciences and pharmaceuticals. It serves as a model for how home-grown innovation can achieve global impact. And it contributes substantially to the nation’s economy, employment, exports, and scientific influence.
